Intellia reported that its in vivo CRISPR therapy lonvoguran ziclumeran (lonvo-z) met the primary endpoint in the Phase 3 HAELO study for hereditary angioedema. The company said the treatment reduced swelling attack rates by 87% versus placebo at six months. Intellia also disclosed that just over 60% of treated patients were attack-free during the study period, compared with 11% on placebo, with no serious safety signals reported. The results position lonvo-z for a potential regulatory path as Intellia begins a rolling submission. The readout places in vivo CRISPR therapy further toward becoming a widely validated modality, with commercial expectations tied to durability, safety, and logistics of one-time dosing.